Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group

Cardiovascular Diabetology

Commentary

Jan Skra¹  Nebojsa Lalic²  Paul Valensi³  Stefano Genovese⁴  Oliver Schnell⁵  Eberhard Standl⁵  Antonio Ceriello⁶  Doina Catrinoiu⁷ 

[1] 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, U Nemocnice 1, 128 08, Prague 2, Czech Republic;Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Dr Subotica 13, 11000, Belgrade, Serbia;Department of Endocrinology Diabetology Nutrition, Hôpital Jean VERDIER, Paris 13 University, CINFO, CRNH-IdF, Avenue du 14 Juillet, 93140, Bondy, France;Diabetes and Metabolic Disease Unit, IRCCS MultiMedica, Via Milanese 300, 20099, Sesto San Giovanni, MI, Italy;Forschergruppe Diabetes e.V, Helmholtz Center Munich, Ingolstaedter Landstrasse 1, Neuherberg, 85764, Munich, Germany;Institut d’Investigacions Biomèdiques August Pi I Sunyer—IDIBAPS, Mallorca, 183, 08036, Barcelona, Spain;Internal Medicine Department, Clinical County Emergency Hospital Constanta, Tomis Blvd. No. 145, 900591, Constanta, Romania;

关键词: Metformin;    Acarbose;    Insulin Glargine;    Insulin Degludec;    European Medicine Agency Guideline;   

DOI  :  10.1186/s12933-016-0357-x

 received in 2016-02-06, accepted in 2016-02-11,  发布年份 2016

来源: Springer

【 摘 要 】

The 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group was held during the annual meeting on 30 October 2015 in Munich. This summit was organized in light of recently published and numerous ongoing CVOTs on diabetes, which have emerged in response to the FDA and the EMA Guidelines. The CVOT Summit stands as a novel conference setup, with the aim of serving as a reference meeting for all topics related to CVOTs in diabetes. Members of the steering committee of the D&CVD EASD Study Group constitute the backbone of the summit. It included presentations of key results on DPP-4 inhibitors, GLP-1-Analogues, SGLT-2 inhibitors, acarbose and insulins. Diabetologists’ and cardiologists’ perspective on the potential need of new study designs were also highlighted. Furthermore, panel discussions on the design of CVOTs on diabetes were included in the program. The D&CVD EASD Study Group will continue its activity. In-depth discussions and presentations of new CVOTs like LEADER, will be resumed at the 2nd CVOT on diabetes of the D&CVD EASD Study Group, which will be held from 20–22 October 2016 in Munich (http://www.dcvd.org).

【 授权许可】

CC BY   
© Schnell et al. 2016